| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Marin Veldic | Q75191736 |
| P2093 | author name string | Alessandro Guidotti | |
| Erminio Costa | |||
| Dennis R Grayson | |||
| John M Davis | |||
| Erbo Dong | |||
| Xianquan Zhang | |||
| James Auta | |||
| P2860 | cites work | An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability | Q24544035 |
| In psychosis, cortical interneurons overexpress DNA-methyltransferase 1 | Q24556666 | ||
| DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains | Q24630392 | ||
| A decrease of reelin expression as a putative vulnerability factor in schizophrenia | Q24657918 | ||
| GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons | Q28142612 | ||
| A framework for consciousness | Q28205764 | ||
| The physiological role of 5-HT2A receptors in working memory | Q28211470 | ||
| Role of the reelin signaling pathway in central nervous system development | Q28214353 | ||
| Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning | Q28217153 | ||
| Imidazenil, a partial positive allosteric modulator of GABAA receptors, exhibits low tolerance and dependence liabilities in the rat | Q28239157 | ||
| Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans | Q28252305 | ||
| GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls | Q28275258 | ||
| Imidazenil, a new anxiolytic and anticonvulsant drug, attenuates a benzodiazepine-induced cognition deficit in monkeys | Q28303866 | ||
| Hallucinations after withdrawal of baclofen | Q28318103 | ||
| Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway | Q28508565 | ||
| Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study | Q29616193 | ||
| The contribution of the anterior cingulate cortex to executive processes in cognition. | Q30578017 | ||
| Input-dependent synaptic targeting of alpha(2)-subunit-containing GABA(A) receptors in synapses of hippocampal pyramidal cells of the rat. | Q31900249 | ||
| Molecular targets for the myorelaxant action of diazepam. | Q31941952 | ||
| Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression | Q33239430 | ||
| Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. | Q33886021 | ||
| Microcolumns in the cerebral cortex | Q33915529 | ||
| GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder | Q33948632 | ||
| Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability. | Q34094299 | ||
| Catching up on schizophrenia: natural history and neurobiology | Q34122141 | ||
| Interneurons unbound | Q34186260 | ||
| Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence | Q34192699 | ||
| Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis | Q34224434 | ||
| Neurosteroid modulation of GABAA receptors | Q34275980 | ||
| Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder | Q34331509 | ||
| Neural synchrony indexes disordered perception and cognition in schizophrenia | Q34368405 | ||
| Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report | Q34395443 | ||
| Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice | Q34398750 | ||
| GABA(A)-receptor subtypes: a new pharmacology | Q34442005 | ||
| The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics | Q34489892 | ||
| Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines | Q34742725 | ||
| A reelin-integrin receptor interaction regulates Arc mRNA translation in synaptoneurosomes | Q34983408 | ||
| GABAA receptors and benzodiazepines: a role for dendritic resident subunit mRNAs | Q34992611 | ||
| Imidazenil prevention of alprazolam-induced acquisition deficit in patas monkeys is devoid of tolerance | Q35054106 | ||
| The pyramidal neuron of the cerebral cortex: morphological and chemical characteristics of the synaptic inputs | Q35420341 | ||
| Hallucinations and baclofen | Q66695372 | ||
| Delayed response deficits produced by local injection of bicuculline into the dorsolateral prefrontal cortex in Japanese macaque monkeys | Q69650035 | ||
| [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics | Q70158501 | ||
| Synaptic target selectivity and input of GABAergic basket and bistratified interneurons in the CA1 area of the rat hippocampus | Q71615814 | ||
| Segregation of serotonin 5-HT2A and 5-HT3 receptors in inhibitory circuits of the primate cerebral cortex | Q73466870 | ||
| Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia | Q73535859 | ||
| Emerging principles of altered neural circuitry in schizophrenia | Q73553170 | ||
| Compartmentalized synthesis and degradation of proteins in neurons. | Q35558440 | ||
| GABA and Schizophrenia: A Review of Basic Science and Clinical Studies | Q35587241 | ||
| GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability. | Q35672461 | ||
| Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction | Q35810087 | ||
| A GABAergic cortical deficit dominates schizophrenia pathophysiology | Q35974076 | ||
| A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia | Q36070114 | ||
| Benzodiazepines in the treatment of schizophrenia: a review and reappraisal | Q36495525 | ||
| GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits | Q36790682 | ||
| Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells | Q37275701 | ||
| Modifications of gamma-aminobutyric acidA receptor subunit expression in rat neocortex during tolerance to diazepam. | Q38358611 | ||
| Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings | Q38465336 | ||
| Biochemical evidence for two classes of GABA receptors in rat brain | Q40251117 | ||
| Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. | Q40417870 | ||
| GABAergic neurons and their role in cortical plasticity in primates | Q40790230 | ||
| Benzodiazepines on trial: a research strategy for their rehabilitation | Q41008175 | ||
| Partial benzodiazepine agonists in schizophrenia: expectations and present clinical findings | Q41983126 | ||
| Columnar architecture sculpted by GABA circuits in developing cat visual cortex | Q42131999 | ||
| Dendritic spine density in schizophrenia and depression | Q43525720 | ||
| A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder | Q43751920 | ||
| Prefrontal cortical representation of visuospatial working memory in monkeys examined by local inactivation with muscimol | Q43766634 | ||
| Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia | Q44014143 | ||
| GABAA receptor subunit mRNA levels are differentially influenced by chronic FG 7142 and diazepam exposure | Q44042421 | ||
| In Patas monkey, glutamic acid decarboxylase-67 and reelin mRNA coexpression varies in a manner dependent on layers and cortical areas | Q44124552 | ||
| Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex | Q44579696 | ||
| Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium | Q44715726 | ||
| Imidazenil: a potent and safe protective agent against diisopropyl fluorophosphate toxicity | Q44771411 | ||
| Specific GABAA circuits for visual cortical plasticity. | Q44797119 | ||
| Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. | Q44824095 | ||
| Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder | Q45003272 | ||
| Two isoforms of glutamate decarboxylase: why? | Q45345778 | ||
| Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. | Q46022290 | ||
| Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors | Q48236672 | ||
| Isodirectional tuning of adjacent interneurons and pyramidal cells during working memory: evidence for microcolumnar organization in PFC. | Q48238408 | ||
| Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex | Q48251166 | ||
| The reduced neuropil hypothesis: a circuit based model of schizophrenia | Q48303124 | ||
| Structural and functional basis for GABAA receptor heterogeneity. | Q48316687 | ||
| Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics | Q48521493 | ||
| Synapse-specific localization of NMDA and GABA(A) receptor subunits revealed by antigen-retrieval immunohistochemistry | Q48546747 | ||
| Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex | Q48632826 | ||
| Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia | Q48826531 | ||
| Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects | Q48855793 | ||
| Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain | Q49018822 | ||
| Differences between somatic and dendritic inhibition in the hippocampus | Q49047383 | ||
| Diazepam treatment of early signs of exacerbation in schizophrenia. | Q51475042 | ||
| Reversible modification of GABAA receptor subunit mRNA expression during tolerance to diazepam-induced cognition dysfunction. | Q51580740 | ||
| Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. | Q52052778 | ||
| P433 | issue | 2 | |
| P921 | main subject | schizophrenia | Q41112 |
| P1104 | number of pages | 15 | |
| P304 | page(s) | 191-205 | |
| P577 | publication date | 2005-04-28 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon | |
| P478 | volume | 180 |
| Q36642249 | A Comprehensive Optogenetic Pharmacology Toolkit for In Vivo Control of GABA(A) Receptors and Synaptic Inhibition |
| Q37800570 | A legacy of discovery: From monoamines to GABA |
| Q41271398 | A methylome-wide mQTL analysis reveals associations of methylation sites with GAD1 and HDAC3 SNPs and a general psychiatric risk score |
| Q37893757 | A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009). |
| Q48087950 | A sensitive period for GABAergic interneurons in the dentate gyrus in modulating sensorimotor gating. |
| Q34135702 | Aberrant regulation of alternative pre-mRNA splicing in schizophrenia |
| Q34151333 | Acute imidazenil treatment after the onset of DFP-induced seizure is more effective and longer lasting than midazolam at preventing seizure activity and brain neuropathology. |
| Q30468184 | Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models |
| Q34084102 | Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression |
| Q38515241 | Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. |
| Q34541215 | An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. |
| Q39651739 | Analysis of the GAD1 promoter: Trans-acting factors and DNA methylation converge on the 5′ untranslated region |
| Q30462828 | Animal models of schizophrenia. |
| Q30386608 | Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection |
| Q42723360 | Antipsychotic subtypes can be characterized by differences in their ability to modify GABAergic promoter methylation |
| Q52151974 | Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. |
| Q36589545 | BDNF-TrkB signaling and neuroprotection in schizophrenia |
| Q30823912 | Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs |
| Q30405706 | Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model |
| Q39419829 | Benzodiazepine Maintenance Treatment in Schizophrenia |
| Q30466591 | Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes |
| Q24652480 | Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation |
| Q49328625 | Cocaine-Induced Changes in Low-Dimensional Attractors of Local Field Potentials in Optogenetic Mice |
| Q39287296 | Cognitive deficits caused by prefrontal cortical and hippocampal neural disinhibition |
| Q34802779 | Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control study |
| Q33762506 | Common variants on Xq28 conferring risk of schizophrenia in Han Chinese |
| Q80855471 | Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia |
| Q58693044 | Current Concepts and Treatments of Schizophrenia |
| Q38264416 | DNA methylation and demethylation as targets for antipsychotic therapy. |
| Q37471987 | DNA methyltransferases1 (DNMT1) and 3a (DNMT3a) colocalize with GAD67-positive neurons in the GAD67-GFP mouse brain. |
| Q34275459 | Design, synthesis, and subtype selectivity of 3,6-disubstituted β-carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents for treatment of alcohol abuse. |
| Q35835236 | Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders |
| Q30576705 | Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits |
| Q36860053 | Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? |
| Q90744653 | Dopamine receptor antagonists effects on low-dimensional attractors of local field potentials in optogenetic mice |
| Q28754545 | Dysfunctional GABAergic inhibition in the prefrontal cortex leading to "psychotic" hyperactivation |
| Q48219115 | Dysregulation of GABAergic neurotransmission in mood disorders: a postmortem study |
| Q60048499 | Epigenetic Alterations in Prenatal Stress Mice as an Endophenotype Model for Schizophrenia: Role of Metabotropic Glutamate 2/3 Receptors |
| Q38602855 | Epigenetic Basis of Mental Illness |
| Q34087810 | Epigenetic GABAergic targets in schizophrenia and bipolar disorder |
| Q38946328 | Epigenetic Mechanisms in Psychiatric Diseases and Epigenetic Therapy |
| Q45297735 | Epigenetic Modifications in Neurological Diseases: Natural Products as Epigenetic Modulators a Treatment Strategy |
| Q38079160 | Epigenetic dysregulation in schizophrenia: molecular and clinical aspects of histone deacetylase inhibitors |
| Q24681663 | Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder |
| Q47881403 | Epigenetic mechanisms in alcohol- and adversity-induced developmental origins of neurobehavioral functioning |
| Q34426222 | Epigenetic mechanisms in schizophrenia. |
| Q30439246 | Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. |
| Q36686917 | Epigenetic targets in GABAergic neurons to treat schizophrenia |
| Q38040133 | Epigenetics of psychoactive drugs |
| Q60649876 | Evidence for disease and antipsychotic medication effects in post-mortem brain from schizophrenia patients |
| Q28293369 | Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake |
| Q27013597 | Functional regulation of GABAA receptors in nervous system pathologies |
| Q26864125 | GABA abnormalities in schizophrenia: a methodological review of in vivo studies |
| Q43287368 | GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients. |
| Q36799974 | GABA(A) receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders |
| Q89963807 | GABAA Receptor β2E155 Residue Located at the Agonist-Binding Site Is Involved in the Receptor Gating |
| Q30421260 | GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism |
| Q41370905 | GABAergic Mechanisms in Schizophrenia: Linking Postmortem and In Vivo Studies |
| Q24597790 | GABAergic interneuron origin of schizophrenia pathophysiology. |
| Q37846896 | Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia |
| Q36925317 | Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. |
| Q39884127 | Genetic disruption of the autism spectrum disorder risk gene PLAUR induces GABAA receptor subunit changes. |
| Q37353278 | Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study |
| Q47953829 | HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals. |
| Q90296315 | HIV gp120-induced neuroinflammation potentiates NMDA receptors to overcome basal suppression of inhibitory synapses by p38 MAPK |
| Q24606593 | Histone modifications, DNA methylation, and schizophrenia |
| Q98891307 | Identification of de novo mutations in prenatal neurodevelopment-associated genes in schizophrenia in two Han Chinese patient-sibling family-based cohorts |
| Q34573086 | Imidazenil and diazepam increase locomotor activity in mice exposed to protracted social isolation. |
| Q37012643 | Imidazenil: a low efficacy agonist at alpha1- but high efficacy at alpha5-GABAA receptors fail to show anticonvulsant cross tolerance to diazepam or zolpidem |
| Q47912489 | Immunohistochemical evaluation of the GABAergic neuronal system in the prefrontal cortex of a DISC1 knockout mouse model of schizophrenia |
| Q26769948 | In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders |
| Q57727112 | Increased neuronal cell number in the dorsal motor nucleus of the vagus in schizophrenia |
| Q35039544 | Inhibition of the betaine-GABA transporter (mGAT2/BGT-1) modulates spontaneous electrographic bursting in the medial entorhinal cortex (mEC) |
| Q38478825 | Interplay of environmental signals and progenitor diversity on fate specification of cortical GABAergic neurons. |
| Q53449540 | Involvement of Epigenetic Modifications of GABAergic Interneurons in Basolateral Amygdala in Anxiety-like Phenotype of Prenatally Stressed Mice. |
| Q37172877 | Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022. |
| Q39365728 | Lmx1a allows context-specific isolation of progenitors of GABAergic or dopaminergic neurons during neural differentiation of embryonic stem cells |
| Q55423202 | Meta-analysis of GABRB2 polymorphisms and the risk of schizophrenia combined with GWAS data of the Han Chinese population and psychiatric genomics consortium. |
| Q36743314 | Metabolomic Profiling of Post-Mortem Brain Reveals Changes in Amino Acid and Glucose Metabolism in Mental Illness Compared with Controls |
| Q28070122 | Metabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review |
| Q37400709 | Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices |
| Q34815864 | Modeling the molecular epigenetic profile of psychosis in prenatally stressed mice |
| Q37960095 | Modulation of ion channels in clinical psychopharmacology: adults and younger people |
| Q37535360 | Modulatory effects of inhibition on persistent activity in a cortical microcircuit model. |
| Q40674790 | Molecular docking based screening of GABA (A) receptor inhibitors from plant derivatives. |
| Q50421452 | Multiple roles of Sonic Hedgehog in the developing human cortex are suggested by its widespread distribution. |
| Q35195048 | Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence |
| Q36804007 | Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling |
| Q24649630 | Nicotine decreases DNA methyltransferase 1 expression and glutamic acid decarboxylase 67 promoter methylation in GABAergic interneurons |
| Q47819976 | Nicotine exposure during adolescence: cognitive performance and brain gene expression in adult heterozygous reeler mice |
| Q34726953 | Past and Present Progress in the Pharmacologic Treatment of Schizophrenia |
| Q21129461 | Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models |
| Q35760210 | Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. |
| Q30490136 | Physiogenomic analysis of localized FMRI brain activity in schizophrenia |
| Q28240120 | Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia |
| Q33319373 | Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. |
| Q36686912 | Rat modeling for GABA defects in schizophrenia |
| Q24530247 | Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia |
| Q59047757 | Reelin in the Years: Controlling Neuronal Migration and Maturation in the Mammalian Brain |
| Q38996374 | Reelin-Haploinsufficiency Disrupts the Developmental Trajectory of the E/I Balance in the Prefrontal Cortex. |
| Q33948009 | Regulation of synaptic plasticity in a schizophrenia model |
| Q42723397 | Schizophrenia and the epigenetic hypothesis |
| Q37792088 | Schizophrenia: Treatment Targets Beyond Monoamine Systems |
| Q30375488 | Searching human brain for mechanisms of psychiatric disorders. Implications for studies on schizophrenia. |
| Q33271010 | Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. |
| Q30467200 | Selective α4β2 nicotinic acetylcholine receptor agonists target epigenetic mechanisms in cortical GABAergic neurons |
| Q90288396 | Sex differences in DEK expression in the anterior cingulate cortex and its association with dementia severity in schizophrenia |
| Q35915861 | Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. |
| Q34215946 | Stem cell therapy: a new approach to the treatment of refractory depression |
| Q36591255 | Stem cell therapy: social recognition recovery in a FASD model |
| Q24596842 | The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice |
| Q34334999 | The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. |
| Q38056122 | The biochemical womb of schizophrenia: A review |
| Q36893751 | The combination of huperzine A and imidazenil is an effective strategy to prevent diisopropyl fluorophosphate toxicity in mice |
| Q36465820 | The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. |
| Q37784829 | The inhibitory GABA system as a therapeutic target for cognitive symptoms in schizophrenia: investigational agents in the pipeline |
| Q48295240 | The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment |
| Q24657941 | The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes |
| Q34146975 | The rise of a new GABA pharmacology |
| Q33624412 | Theranostic Biomarkers for Schizophrenia |
| Q38202190 | Toward the identification of peripheral epigenetic biomarkers of schizophrenia |
| Q41574564 | Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease |
| Q42949861 | Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics |
| Q38060562 | Wnt signaling: role in Alzheimer disease and schizophrenia |
| Q35834884 | Young Women do it Better: Sexual Dimorphism in Temporal Discrimination |
| Q79374900 | [Non-dopaminergic drugs in schizophrenia] |
Search more.